What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market ...

President Donald Trump said in a letter Thursday that he will raise taxes on many imported goods from Canada to 35%, ...

The Health Care Select Sector SPDR® Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of 12 ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

This was the stock's second consecutive day of gains.

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need.

Gilead Shares Rise After US Top Court Ruling on Preventive Coverage By Mariam Sunny and Mrinalika Roy (Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage trials of obeldesivir.